đź“° Full Story
April 19-20, 2026 reports say U.S. drugmaker Eli Lilly is in advanced talks to acquire Boston-based Kelonia Therapeutics for more than $2 billion, with a deal possibly announced imminently and structured to include milestone-linked additional payments.
Kelonia is a clinical-stage biotech developing a next‑generation CAR‑T therapy for multiple myeloma that aims to simplify current CAR‑T manufacturing and potentially avoid chemotherapy, accelerating administration and scalability.
The startup has raised under $60 million to date and was last valued at just above $100 million in 2022, underscoring the premium Lilly would pay.
The acquisition would strengthen Lilly’s oncology portfolio — complementing existing cancer drugs such as Verzenio — and continues a recent strategic push (including the February Orna Therapeutics deal) to diversify beyond its blockbuster weight‑loss and diabetes franchises.
Reuters and other outlets reported the talks; companies had not immediately commented and the transaction remained unverified at publication.
Kelonia’s lead programs are at an early clinical stage, so the acquisition carries development and regulatory risk despite potential commercial upside if the technology proves effective.








đź’¬ Commentary